Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study-Reference-Cited by-同舟云学术

Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: Analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study

Published:2022-09 Issue: Volume:8 Page:146-153
ISSN:2666-3287
Container-title:JAAD International
language:en
Short-container-title:JAAD International

Author:

Miyagi Takuya,Kanai Yasumasa,Murotani Kenta,Okubo Yukari,Honma Masaru,Kobayashi Satomi,Seishima Mariko,Mizutani Yoko,Kitabayashi Hiroki,Imafuku Shinichi

Publisher

Elsevier BV

Subject

Dermatology

Reference38 articles.

1. Psoriasis and psoriatic arthritis overview;Menter;Am J Manag Care,2016

2. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity;Korman;Dermatol Online J,2015

3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Sbidian;Cochrane Database Syst Rev,2020

4. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using Bayesian and Frequentist network meta-analyses;Warren;Dermatol Ther (Heidelb),2020

5. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab;Torii;J Dermatol,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. This Month in JAAD International: December 2023: Patient-reported outcome measures;Journal of the American Academy of Dermatology;2023-12

2. This Month in JAAD International: July 2023: Quality of life and itch;Journal of the American Academy of Dermatology;2023-07

3. Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis;Journal of Dermatological Treatment;2023-05-31